Joseph Ahmed Foundation (JAF)   Report issue

Foundation Phase 2
Founded: Matawan NJ United States (2016)

Organization Overview

First Clinical Trial
2019
NCT03778996
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Joseph Ahmed Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neuroectodermal Tumors, Primitive, Peripheral (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 4